Compare SPCE & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | SENS |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Industrial Machinery/Components |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.2M | 301.2M |
| IPO Year | 2017 | 2014 |
| Metric | SPCE | SENS |
|---|---|---|
| Price | $4.79 | $6.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $3.06 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 41.6M | 902.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,544,000.00 | ★ $16,389,000.00 |
| Revenue This Year | $2,270.73 | $74.15 |
| Revenue Next Year | $880.03 | $58.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $2.13 | $0.41 |
| 52 Week High | $8.90 | $8.75 |
| Indicator | SPCE | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 61.87 |
| Support Level | $2.74 | $6.62 |
| Resistance Level | $4.90 | $7.45 |
| Average True Range (ATR) | 0.98 | 0.39 |
| MACD | 0.17 | 0.14 |
| Stochastic Oscillator | 36.75 | 84.76 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.